Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Chugai and Roche announce positive trial results for RoACTEMRA

Chugai and Roche announce positive trial results for RoACTEMRA

20th November 2009

Chugai and Roche have revealed that the drug they developed in cooperation, RoACTEMRA, (tocilizumab) yielded a successful outcome as part of a recent study.

The product successfully met its primary endpoint in a paediatric study of systemic onset Juvenile Idiopathic Arthritis (sJIA) of noticeably curbing symptoms of the disease.

According to the companies, this is particularly good news for child sufferers, as there is currently no approved treatment available for the condition.

Some of the symptoms of sJIA include rashes, fever, infections and anaemia.

William Burns, chief executive of Roche’s pharmaceuticals division, explained: “This is a particularly debilitating disease affecting the entire body in which morbidity is high and there is much need for new treatment options in this area.”

In other Chugai news, the firm revealed earlier this month that its product Avastin has been approved by the ministry of health, labour and welfare to treat unresectable advanced or recurrent non-squamous non-small cell lung cancer.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.